<code id='7329A88436'></code><style id='7329A88436'></style>
    • <acronym id='7329A88436'></acronym>
      <center id='7329A88436'><center id='7329A88436'><tfoot id='7329A88436'></tfoot></center><abbr id='7329A88436'><dir id='7329A88436'><tfoot id='7329A88436'></tfoot><noframes id='7329A88436'>

    • <optgroup id='7329A88436'><strike id='7329A88436'><sup id='7329A88436'></sup></strike><code id='7329A88436'></code></optgroup>
        1. <b id='7329A88436'><label id='7329A88436'><select id='7329A88436'><dt id='7329A88436'><span id='7329A88436'></span></dt></select></label></b><u id='7329A88436'></u>
          <i id='7329A88436'><strike id='7329A88436'><tt id='7329A88436'><pre id='7329A88436'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:explore    - browse:7496
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment